Ovaleap (Follitropin Alfa (Genetical Recombination))

Follitropin alfa mimics the natural hormone FSH by binding to FSH receptors on ovarian granulosa cells. This activates intracellular signalling that promotes cell proliferation, estradiol production, and the maturation of ovarian follicles, ultimately leading to ovulation or the availability of mature oocytes for assisted reproduction.

The dose of Ovaleap is individualized. A qualified prescriber determines the amount, frequency, and duration based on the patient’s ovarian reserve, treatment protocol, and response to monitoring. Dosing regimens can vary widely between different fertility programmes.

Ovaleap is intended for use before conception to stimulate follicular development. It is not indicated for use during an established pregnancy, and safety data for breastfeeding are limited. Women who become pregnant while on treatment should discontinue use and consult their healthcare provider.

To request Ovaleap, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Ovaleap is a recombinant FSH produced by genetic recombination, offering high purity and consistent activity compared with urinary‑derived FSH preparations. Clinical efficacy is comparable, but recombinant products like Ovaleap often have lower risk of immunogenic reactions and more predictable dosing.

Ovaleap must be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. If the product has been kept at room temperature for more than 24 hours, discard it according to local regulations.

Ovaleap is supplied as a sterile solution for subcutaneous injection. It is typically reconstituted with the provided diluent and administered using a fine‑gauge needle into the abdomen or thigh, following the dosing schedule prescribed by the treating fertility specialist.

The most serious risks include severe ovarian hyperstimulation syndrome (OHSS), which can cause rapid weight gain, fluid accumulation, and thromboembolic events, as well as ovarian torsion, multiple pregnancy, and rare allergic reactions such as anaphylaxis. Patients should be monitored closely for these complications.

Ovaleap should not be used in individuals with known hypersensitivity to follitropin alfa or any excipients, in patients with active ovarian cysts, uncontrolled thyroid disease, estrogen‑dependent tumors, or in women who are already pregnant. Contra‑indications are assessed by the prescribing clinician.